Cancer is on the rise in China. In 2014, the country saw 2.3 million deaths from the disease and 3.8 million new cases, accounting for more than one fifth of premature deaths and more than a quarter of new cancer cases worldwide.

In an era with unprecedented longevity and declining birth rates, we are approaching a future defined by more people aged over 60 than under 15 for the first time in human history.

After a year-long debate, the Japanese government is on the cusp of announcing their final decision on the reform of its drug pricing system.

At Bayer Pharmaceuticals, we focus on researching, developing specialty-focused innovative medicines that provide significant clinical benefit and value in areas of high unmet medical need such as cardiology and oncology.

Japan is an aging society and the prevalence of cancer and cardiovascular diseases is increasing.

Intellectual Property (IP) protection is the lifeblood of the research-based pharmaceutical industry.

Member States and the European Parliament are currently discussing the European Commission’s legislative proposal for a cooperative approach on Health Technology Assessment.

The United States promotes strong and effective IP protection around the world by means of the United States Patent and Trademark Office (USPTO) and its international intellectual property (IP) attaché program.